Will G6 products still be shipped to patients?

Yes, G6 will still be available to patients once G7 launches. Some patients should continue using G6 while G7 insurance coverage is expanded, and connectivity with connected insulin pumps is rolled out. 

  • #1 in Accuracy1: Dexcom G7 has an overall MARD of 8.1% for pediatrics and 8.2% for adults as published in our U.S. pivotal trial data. FreeStyle Libre 3 (L3) is FDA cleared with an overall accuracy of 8.9% for adults and 9.4% for pediatrics as listed in their U.S. User Guide##

  • Less Downtime**: G7 warms up in just 30 minutes after which you can immediately make insulin dosing decisions.  L3 requires 12 hours before dosing decisions##, which would make it unable to work with a connected system in the future. Dexcom CGM Systems adherence and persistence is nearly 30% higher with Dexcom over Libre.13 

  • More Reliable: G7 has an automatic predictive low alert to help prevent a low, while L3’s threshold alerts only notify you the minute after you went low##

  • Medicare Support: RT-CGM is recommended for older adults, per ADA11 and AACE12 guidelines, and G6 and G7 both fulfill Medicare requirements.  L3, Abbott’s only RT-CGM, does not fulfill Medicare requirements due to the lack of a dedicated receiver. 

  • Most Proven Outcomes: Dexcom generates the most amount of clinical data and has been evaluated in a greater number of studies1 – over 300 clinical trials – on the value and benefit of CGM across the spectrum of diabetes states and methodologies to remain focused on measuring and driving the best outcomes. 

  • Proven Connectivity Platform: Dexcom G7 is already part of Dexcom’s industry leading connected CGM ecosystem1 to allow patients to manage their diabetes with the insulin and lifestyle hardware and software that works best for them.  With 4 years of proven connectivity and a saleable real-time API, Dexcom is the only CGM brand to offer AID and have a larger connectivity platform. L3 explicitly has an AID contraindication.## 

  • Overall Patient Experience: Dexcom is the #1 most recommended CGM brand by both patients and HCPs 6, #1 in patient retention7, and #1 in patient satisfaction§§. Libre users switch to Dexcom 3x more frequently than Dexcom users switch to Libre8



     

    *Smart device, sold separately, required to display readings on watch. †Compatible smart devices sold separately. For a list of compatible devices, visit dexcom.com/compatibility. ||Results obtained with a prior generation Dexcom CGM System. ¶Separate Follow app and internet connection required. Users should always confirm readings on the Dexcom G6 app or receiver before making treatment decisions. #Compared to a prior generation Dexcom CGM System. **Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer. ††Healthcare providers can register for Dexcom Clarity at clarity.dexcom.com/professional/ registration. ‡‡An internet connection is required for patients to send their glucose data to Dexcom Clarity via a compatible smart device: dexcom.com/compatibility. Healthcare providers will only be able to view a patient’s glucose data if the patient elects to share it with them through Dexcom Clarity. §§Comparison of NPS scores of Dexcom, Abbott, and Medtronic, Seagrove Survey 2021 Patient Perspectives. ##Libre 3 user guide 

    1 Dexcom, data on file, 2022. 2 Beck, RW, et al. JAMA. 2017;317(4):371-378. 3 Welsh JB, et al. J Diabetes Sci Technol. Jun 13 2022:19322968221099879. 4 Dexcom G7 CGM System User Guide. 2022. 5 Managed Markets Insights & Technology, LLC. MMIT Analytics, June 2022. 6 dQ&A US Q1 2021 Diabetes Connections Patient Panel Report. 2021;69-72.  7 IQVIA, February 2022. 8 Data on File. IQVIA 2022 9 Dexcom G7 User Guide. 10 GoodRx Program: Set buy down per finance of $200 for sensors and transmitters 11 American Diabetes Association. Standards of Medical Care in Diabetes - 2023. Diabetes Care. 2023;45(S1):S1-291. 12 Grunberger G, et al. Endocr Pract. 2021;27(6):505-537. 13 IQVIA, February 2022 - According to IQVIA, patient retention data is the sum of persistent and reinitiated patients. Persistent patients are the patients who remain on therapy without interruption (days’ supply + 30-day grace period). Reinitiated patients are the group that has interruption in use. These data are for new IIT patients across all channels from September 2020 to August 2021. 

Contact Us

If you are a healthcare provider and want to learn more about Dexcom, please fill out the form and a representative will contact you. If you are a Dexcom User or Patient, please contact Dexcom here.

Contact Reason

Please note: To ensure a successful transaction, please provide information that matches the Provider’s medical license information. A valid business address is required for a request to be fulfilled.

Do not include prefix (Mr., Mrs., Dr.)
As listed on Provider’s medical license (no MD, Jr., Sr.)
Please use the Provider’s NPI
Please provide Facility/Office address Only- We will not ship to home address
Is your patient on a connected pump device?

 

By choosing to request info, you are granting Dexcom, Inc. permission to process your personal information to send you additional information and promotional communications related to Dexcom products. You may opt-out of these communications at any time. Dexcom respects the privacy and confidentiality of your personal information. The information you provide will be sent securely and subject to the Dexcom Terms of Use and Privacy Policy.